| Objective To apply the meta-analysis and compare the efficacy and medication safety of oxitinib combined with immune checkpoint blockers and oxitinib monotherapy in patients with advanced non-small cell lung cancer.Methods The literatures about the combination of oxitinib and immune checkpoint blocking treatment for non-small cell lung cancer in PubMed,SAGE,Embase,Chinese National Knowledge Infrastructure (CNKI),Cochrane,UpToDate,JAMA,etc.from July 2000 to July 2020 were manually searched.The evaluation principle of Cochrane Evidence-based Medicine Center was used to evaluate the quality of literatures.Results Finally,15 eligible randomized controlled trials were included,with a total of 3106 patients.In terms of therapeutic efficacy,there was no significant difference of the objective remission rate between the oxitinib combined with immune checkpoint blocker treatment group and the oxitinib treatment group,difference of the objective remission rate was not statistically significant and the oxltinib treatment group (OR:1.59,95%CI:1.36-1.87,P>0.05),while difference of the progression-free survival time was statistically significant (OR:0.89,95%CI:0.74-1.07,P<0.00001).In terms of medication safety,the incidence of adverse reaction events in the oxitinib combined with immune checkpoint blocker treatment group was lower than that in the oxitinib treatment group(RR:0.67,95%CI:0.56-0.81,P<0.0001).Conclusion Oxitinib combined with immune checkpoint blockers treatment is superior to oxitinib monotherapy in the treatment of advanced non-small cell lung cancer,and the incidence of adverse reaction events has not increased significantly. |
